Taipei Exchange - Delayed Quote TWD

Microbio Co., Ltd. (4128.TWO)

24.15
-0.35
(-1.43%)
At close: 1:13:39 PM GMT+8
Loading Chart for 4128.TWO
  • Previous Close 24.50
  • Open 24.90
  • Bid 24.10 x --
  • Ask 24.15 x --
  • Day's Range 24.05 - 25.25
  • 52 Week Range 20.00 - 45.48
  • Volume 812,478
  • Avg. Volume 1,256,144
  • Market Cap (intraday) 14.204B
  • Beta (5Y Monthly) 1.30
  • PE Ratio (TTM) --
  • EPS (TTM) -1.88
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jun 16, 2023
  • 1y Target Est --

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia. It also involved in the trading of organic foods; sale of beverages; provision of technology development, transfer, and consultation services; and publishing of magazine, as well as offers business consulting services. Microbio Co., Ltd. was incorporated in 2000 and is based in Taipei City, Taiwan.

www.twmicrobio.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4128.TWO

View More

Performance Overview: 4128.TWO

Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4128.TWO
26.82%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
5.98%

1-Year Return

4128.TWO
38.45%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
0.49%

3-Year Return

4128.TWO
46.51%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
34.14%

5-Year Return

4128.TWO
6.48%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
100.32%

Compare To: 4128.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4128.TWO

View More

Valuation Measures

Annual
As of 5/21/2025
  • Market Cap

    14.41B

  • Enterprise Value

    12.29B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    8.19

  • Price/Book (mrq)

    1.49

  • Enterprise Value/Revenue

    6.96

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -62.84%

  • Return on Assets (ttm)

    -2.01%

  • Return on Equity (ttm)

    -10.50%

  • Revenue (ttm)

    1.77B

  • Net Income Avi to Common (ttm)

    -1.11B

  • Diluted EPS (ttm)

    -1.88

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.69B

  • Total Debt/Equity (mrq)

    5.06%

  • Levered Free Cash Flow (ttm)

    -14.32M

Research Analysis: 4128.TWO

View More

Company Insights: 4128.TWO

Research Reports: 4128.TWO

View More

People Also Watch